JP2023546923A5 - - Google Patents
Info
- Publication number
- JP2023546923A5 JP2023546923A5 JP2023524352A JP2023524352A JP2023546923A5 JP 2023546923 A5 JP2023546923 A5 JP 2023546923A5 JP 2023524352 A JP2023524352 A JP 2023524352A JP 2023524352 A JP2023524352 A JP 2023524352A JP 2023546923 A5 JP2023546923 A5 JP 2023546923A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disorder
- patient
- suramin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104350P | 2020-10-22 | 2020-10-22 | |
| US63/104,350 | 2020-10-22 | ||
| PCT/US2021/055908 WO2022087174A1 (en) | 2020-10-22 | 2021-10-20 | Intranasal administration of suramin for treating nervous system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546923A JP2023546923A (ja) | 2023-11-08 |
| JP2023546923A5 true JP2023546923A5 (enExample) | 2024-10-28 |
Family
ID=81289355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524352A Withdrawn JP2023546923A (ja) | 2020-10-22 | 2021-10-20 | 神経系障害を処置するためのスラミンの鼻腔内投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230390226A1 (enExample) |
| EP (1) | EP4229035A4 (enExample) |
| JP (1) | JP2023546923A (enExample) |
| CN (1) | CN116802174A (enExample) |
| AU (1) | AU2021366666A1 (enExample) |
| CA (1) | CA3194818A1 (enExample) |
| IL (1) | IL302223A (enExample) |
| WO (1) | WO2022087174A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11080495B2 (en) * | 2018-10-25 | 2021-08-03 | Unified Information Devices, LLC | Animal motion and temperature monitoring |
| CN116867487A (zh) * | 2020-07-29 | 2023-10-10 | 完美日光有限公司 | 苏拉明的制造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| CN118697876A (zh) * | 2017-02-09 | 2024-09-27 | 完美日光有限公司 | 用于自闭症谱系障碍药物治疗的方法 |
| JP7749169B2 (ja) * | 2019-06-07 | 2025-10-06 | クヴァトリス セラピューティクス， インコーポレイテッド | 中枢神経系障害を処置するための組成物および方法 |
-
2021
- 2021-10-20 US US18/033,167 patent/US20230390226A1/en active Pending
- 2021-10-20 IL IL302223A patent/IL302223A/en unknown
- 2021-10-20 CA CA3194818A patent/CA3194818A1/en active Pending
- 2021-10-20 WO PCT/US2021/055908 patent/WO2022087174A1/en not_active Ceased
- 2021-10-20 AU AU2021366666A patent/AU2021366666A1/en not_active Abandoned
- 2021-10-20 CN CN202180085815.2A patent/CN116802174A/zh active Pending
- 2021-10-20 JP JP2023524352A patent/JP2023546923A/ja not_active Withdrawn
- 2021-10-20 EP EP21883840.7A patent/EP4229035A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101312311B1 (ko) | 약학적 코 제형물 및 이의 이용 방법 | |
| JP2023546923A5 (enExample) | ||
| JP2017206560A (ja) | モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物 | |
| Chang et al. | Cough as an adverse effect on inhalation pharmaceutical products | |
| EP3033089A2 (en) | Uses of phospholipid conjugates of synthetic tlr7 agonists | |
| JP2022535920A5 (enExample) | ||
| HRP20192111T1 (hr) | Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g | |
| EP2640410B1 (de) | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase | |
| CA2792913C (en) | Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| KR20150095896A (ko) | 염증성 및/또는 알레르기 질환의 치료를 위한 레보카바스틴 및 플루티카손 푸로에이트의 조합물 | |
| US20090215717A1 (en) | Sulfated oligosaccharides | |
| US11291672B2 (en) | Betamethasone oral spray formulation and method of use to treat ataxia | |
| WO2022087174A1 (en) | Intranasal administration of suramin for treating nervous system disorders | |
| US9265755B2 (en) | Stem cell administration to reduce TNF-α level in CSF of an autism spectrum disorder or pervasive development disorder patient | |
| CA3155464A1 (en) | Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives | |
| AT523662B1 (de) | Gold-haltige Mittel zur Behandlung von Lungeninfektionen | |
| JP2023549837A5 (enExample) | ||
| JP2022062596A (ja) | エピナスチン又はその塩を含有する花粉破裂抑制剤 | |
| ES2890453T3 (es) | Carbamatos de galantamina para el tratamiento del autismo | |
| CN105796540A (zh) | 托芬那酸在制备治疗亨廷顿氏症药物中的应用 | |
| Singh et al. | Application of nano-and micro-particle-based approaches for selected bronchodilators in management of asthma | |
| Belskaya et al. | ANTICONVULSANT ACTIVITY OF ORIGINAL VALPROIC ACID AMINOETHERS IN CHOLINESTERASE INHIBITOR POISONING | |
| CN121971469A (en) | Bacopa monnieri glycoside 2 targeting post-stroke AQP1 target of mice and application of Bacopa monnieri glycoside 2 in stroke intervention | |
| JP2024532288A5 (enExample) | ||
| CN106265612A (zh) | 龙血素c在制备防治中枢神经系统疾病药物中的应用 |